The box jellyfish sting can deliver one of the most deadly venoms on the planet. There are more than 50 species of box jellyfish around the world, eight of which are potentially deadly. Some can kill ...

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is exploring a potential sale and is seeing interest from private equity ...

Separate from the refinancing option, Bausch + Lomb is exploring a sale of itself, which could draw interest from private equity buyers. Wed, 18 Sep, 2024 - 10:13 Bausch Health is working with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Blackstone, Advent International and TPG are among a long list of private equity firms studying bids for ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, ...

Firm explores completing spinoff of stake in Bausch + Lomb Bausch + Lomb is separately mulling a sale of itself The effort to push out maturities on some of the company’s debt is aimed at vanquishing ...

Laval, Canada-based Bausch Health announced plans in 2020 to separate Bausch + Lomb into an independent, publicly traded company. The intent was to separate the eye care business, which includes ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times reported ...